🔗 Share this article

While America continues making historic changes to its vaccine guidelines, an unexpected name has emerged somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who first made her name by casting doubt on Covid shots during the global health crisis and has focused upon potential deaths after Covid immunization in her short position at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Vaccine Program

Public health authorities had intended to announce sweeping revisions to the pediatric vaccine schedule earlier this month, synchronizing the US with the Danish immunization schedule, it is understood – a significant shift that would put the US out of alignment with many the international standard with insufficient data for improved outcomes. The announcement has been delayed until the coming year.

In place of the top vaccines chief, Høeg is scheduled to present at the event. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to head the division this year.

Consolidating Power at the Regulatory Body

Høeg's temporary position could signify a tighter collaboration between the drug and vaccine branches as Høeg and Prasad strengthen their influence at the FDA – and it points to a renewed priority upon rolling back already-approved immunizations at the FDA.

Høeg has often pushed for ending some pediatric immunization guidelines in the US to become more in line with the Danish model, a country with universal health coverage and a citizenry approximately the size of the state of Wisconsin.

So far public appearances, she has persisted in emphasizing on immunizations – typically the domain of Prasad, director of the FDA’s CBER – as opposed to drug regulation.

Concerns Over Expertise

The appointee has no obvious track record in medication creation, regulation or management, which has been customary for previous leaders of the biologics center. She has served at the FDA as a top consultant to the commissioner and CBER since March.

“She doesn’t seem to have any of the qualifications” for leading the drug-regulation department, remarked Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in managing a large organization. She lacks background in drug approvals.”

Past heads of CBER would “be deeply familiar with regulatory frameworks and the science of medication creation”, said Dr. Janet Woodcock. “Frankly, she has not acquired the sort of resume that previous people who headed CBER have had.”

The drug center has an immense portfolio at the FDA, she stated.

“The public just focuses on the new drug program, but the generic program clears thousands of generic drugs. There’s a biologic copycat branch, OTC medication office and more, and each of these need to be looked after,” Dr. Woodcock explained. “The area you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a major administrative element to the job, which manages in excess of 5,000 staff members. “It’s a massive management job, if you execute it properly,” Woodcock said.

Official Statement and Controversial Initiatives

In response to inquiries about Høeg’s credentials and whether this assignment represents greater collaboration among FDA leaders on vaccines, a press secretary stated that the “inquiries rely on incorrect presumptions”.

“Her experience is consistent with the responsibilities of her role,” the representative stated, noting the months Dr. Høeg spent advising the agency head on “pharmaceutical safety and oversight research, including computational safety modeling and immunization monitoring”.

In her interim role, Dr. Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a disputed one-day therapy clearance system that allegedly worried her former heads. “By what process are these drugs being selected for this voucher program? Who takes the calls?” Dr. Howard said. “There is a lot of lack of transparency happening at the FDA right now.”

In general, he said, “the agency seems to be moving towards more relaxed regulations of all drugs, aside from shots.”

Documented Past Work on Immunizations

Concerning vaccines, Dr. Høeg has a clearer, if problematic, history, Howard observe. She authored a study using unconfirmed volunteer-provided data to determine the incidence of myocarditis after COVID-19 vaccination. She advised the Florida surgeon general Joseph Ladapo, who was said to have altered data to imply COVID-19 vaccines are more dangerous than they are.

Part of her “desired changes” for the incoming government included changing regulations for novel immunizations and discontinuing “unnecessary” immunizations, she stated following the vote on a audio program. At the FDA, Høeg has according to sources floated the idea of excluding young men from getting Covid vaccines.

“She’s an all-around ideologue who commences with her preconceived notions and works backwards to retrofit the evidence in a highly disingenuous, fraudulent way,” Dr. Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of fellow dissenters, {like|